Asacol 400 mg

DRUG3 trials

Sponsors

Warner Chilcott, Tillotts Pharma AG

Conditions

Acute Ulcerative ColitisUlcerative Colitis

Phase 3

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

CompletedNCT00713310

Warner ChilcottUlcerative Colitis

Start: 2008-12-31End: 2011-03-31Updated: 2012-04-05

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

TerminatedNCT01004185

Warner ChilcottUlcerative Colitis

Start: 2009-10-31End: 2011-03-31Updated: 2012-05-25

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

CompletedNCT01903252

Tillotts Pharma AGAcute Ulcerative Colitis

Start: 2013-07-31End: 2016-11-30Updated: 2018-08-08

Related Papers

Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis

Clinical Gastroenterology and Hepatology2020-12-038 citations

Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis

Alimentary Pharmacology & Therapeutics2017-06-0146 citations

P-102 The Regulatory and Legal Complexity of the Multicentre, Multinational Clinical Trial with TP05

Inflammatory Bowel Diseases2016-02-05